Cargando…
Prostate cancer in omics era
Recent advances in omics technology have prompted extraordinary attempts to define the molecular changes underlying the onset and progression of a variety of complex human diseases, including cancer. Since the advent of sequencing technology, cancer biology has become increasingly reliant on the gen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442907/ https://www.ncbi.nlm.nih.gov/pubmed/36064406 http://dx.doi.org/10.1186/s12935-022-02691-y |
_version_ | 1784782928634445824 |
---|---|
author | Gholami, Nasrin Haghparast, Amin Alipourfard, Iraj Nazari, Majid |
author_facet | Gholami, Nasrin Haghparast, Amin Alipourfard, Iraj Nazari, Majid |
author_sort | Gholami, Nasrin |
collection | PubMed |
description | Recent advances in omics technology have prompted extraordinary attempts to define the molecular changes underlying the onset and progression of a variety of complex human diseases, including cancer. Since the advent of sequencing technology, cancer biology has become increasingly reliant on the generation and integration of data generated at these levels. The availability of multi-omic data has transformed medicine and biology by enabling integrated systems-level approaches. Multivariate signatures are expected to play a role in cancer detection, screening, patient classification, assessment of treatment response, and biomarker identification. This review reports current findings and highlights a number of studies that are both novel and groundbreaking in their application of multi Omics to prostate cancer. |
format | Online Article Text |
id | pubmed-9442907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94429072022-09-06 Prostate cancer in omics era Gholami, Nasrin Haghparast, Amin Alipourfard, Iraj Nazari, Majid Cancer Cell Int Hypothesis Recent advances in omics technology have prompted extraordinary attempts to define the molecular changes underlying the onset and progression of a variety of complex human diseases, including cancer. Since the advent of sequencing technology, cancer biology has become increasingly reliant on the generation and integration of data generated at these levels. The availability of multi-omic data has transformed medicine and biology by enabling integrated systems-level approaches. Multivariate signatures are expected to play a role in cancer detection, screening, patient classification, assessment of treatment response, and biomarker identification. This review reports current findings and highlights a number of studies that are both novel and groundbreaking in their application of multi Omics to prostate cancer. BioMed Central 2022-09-05 /pmc/articles/PMC9442907/ /pubmed/36064406 http://dx.doi.org/10.1186/s12935-022-02691-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Hypothesis Gholami, Nasrin Haghparast, Amin Alipourfard, Iraj Nazari, Majid Prostate cancer in omics era |
title | Prostate cancer in omics era |
title_full | Prostate cancer in omics era |
title_fullStr | Prostate cancer in omics era |
title_full_unstemmed | Prostate cancer in omics era |
title_short | Prostate cancer in omics era |
title_sort | prostate cancer in omics era |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442907/ https://www.ncbi.nlm.nih.gov/pubmed/36064406 http://dx.doi.org/10.1186/s12935-022-02691-y |
work_keys_str_mv | AT gholaminasrin prostatecancerinomicsera AT haghparastamin prostatecancerinomicsera AT alipourfardiraj prostatecancerinomicsera AT nazarimajid prostatecancerinomicsera |